Abstracts tagged "anti-TNF therapy"

Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting
Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?
Proton Rahman¹, Algis Jovaisas², William Bensen³, Wojciech Olszynski⁴, Anna Jaroszynska⁵, Philip Baer⁶, Maqbool Sheriff⁷, Dalton Sholter⁸, Eliofotisti Psaradellis⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹ and May Shawi¹⁰, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Burlington, ON, Canada, ⁶Private Practice, Scarborough, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…
Abstract Number: 2521 • 2014 ACR/ARHP Annual Meeting
Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
Tsutomu Takeuchi¹, Yutaka Ishii², Kimie Tanaka³, Yoshifumi Ukyo⁴ and Hiroshi Sekine⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Medical Affaires, Janssen Pharmaceutical K.K, Tokyo, Japan, ³Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan, ⁴Biostatistics Devision, Janssen Pharmaceutical K.K., Japan, Tokyo, Japan, ⁵Medical Affaires, Janssen Pharmaceutical K.K., Tokyo, Japan
Background/Purpose The GO-FORTH, phase 2/3 clinical trial was conducted to examine the efficacy and safety of Golimumab (GLM) plus MTX in Japanese patients (pts) with…
Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Philip J. Mease¹, Roy Fleischmann², Owen Davies³, Tommi Nurminen⁴ and Désirée van der Heijde⁵, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…
Abstract Number: 567 • 2014 ACR/ARHP Annual Meeting
Use of Monotherapy Anti-Tnf Agents in Ankylosing Spondylitis Patients from the rhumadata® Registry: 8-Year Comparative Effectiveness of Adalimumab, Etanercept and Infliximab
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada
Background/Purpose: Anti-TNF agents namely adalimumab (ADA), etanercept (ETA) and infliximab (INF) are approved for the treatment of signs and symptoms of ankylosing spondylitis. Their efficacy…
Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting
Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom
Frances Humby¹, Stephen Kelly¹, Angela V. Bedenbaugh², Nawab Qizilbash^3,4, Jochen Dunkel⁵, Belén SanJose³, Ignacio Mendez³, Jennifer Timoshanko⁶ and Jeyanesh Tambiah², ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²UCB Pharma, Smyrna, GA, ³OXON Epidemiology, London, United Kingdom, ⁴Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Slough, United Kingdom
Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…
Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting
Serum Survivin in Early Rheumatoid Arthritis
Adrian Levitsky¹, Malin Erlandsson², Maria Bokarewa² and Ronald F. van Vollenhoven³, ¹The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…
Abstract Number: 1550 • 2014 ACR/ARHP Annual Meeting
Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting
Proton Rahman¹, Denis Choquette², William Bensen³, Majed Khraishi⁴, Saeed Shaikh⁵, Regan Arendse⁶, Isabelle Fortin⁷, Andrew Chow⁸, Maqbool Sheriff⁹, Eliofotisti Psaradellis¹⁰, John S. Sampalis¹⁰, Susan Otawa¹¹, Francois Nantel¹², Allen J Lehman¹¹ and May Shawi¹², ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada
Background/Purpose Spondyloarthritis, including psoriatic arthritis (PsA), is characterized by inflammatory arthritis affecting axial and peripheral joints. It is commonly associated with extra-articular and peri-articular manifestations…
Abstract Number: 566 • 2014 ACR/ARHP Annual Meeting
Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Désirée M. van der Heijde¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Owen Davies⁵, Tommi Nurminen⁴ and Jürgen Braun⁶, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany
Background/Purpose The impact of certolizumab pegol (CZP) on clinical and Magnetic Resonance Imaging outcomes in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS)…
Abstract Number: 75 • 2014 ACR/ARHP Annual Meeting
Robust Identification of Anti-TNF Non-Responders in RA from Blood
Ty Thomson, Reynald Lescarbeau, David Drubin, David Fryburg, David de Graaf, Renée Deehan, Daphna Laifenfeld and Aaron Van Hooser, Selventa, Cambridge, MA
Background/Purpose: The number of biologic therapies approved for use in treating rheumatoid arthritis (RA) has grown steadily over the past 15 years. While many patients…
Abstract Number: 2500 • 2014 ACR/ARHP Annual Meeting
Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients
Jacob Sode^1,2,3, Ulla Vogel⁴, Steffen Bank^5,6, Paal Skytt Andersen⁷, Merete Lund Hetland^8,9, Henning Locht³, Niels H. H. Heegaard^10,11 and Vibeke Andersen^1,5,12,13, ¹Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ²Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, ³Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ⁴National Research Centre for the Working Environment, Copenhagen, Denmark, ⁵Medical Department, Viborg Regional Hospital, Viborg, Denmark, ⁶Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁷Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ¹⁰Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ¹¹Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark, ¹²Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, ¹³Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis PatientsBackground/Purpose: In a recent study (paper in press) of Danish rheumatoid…
Abstract Number: 1528 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies
Ronald van Vollenhoven¹, S. B. Cohen², Philip J. Mease³, Charles G. Peterfy⁴, Wolfgang Spieler⁵, Judith Boice⁶, Sean Curtis⁷, Qing Li⁷, Ruji Yao⁸, Richard Baumgartner⁷ and Holly Weng⁸, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Metroplex Clinical Research Center, Dallas, TX, ³University of Washington, Seattle, WA, ⁴Spire Sciences LLC, Boca Raton, FL, ⁵Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁶Merck Research Laboratories, Whitehouse Station, NJ, ⁷Merck & Co., Inc, Whitehouse Station, NJ, ⁸Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Novel, targeted small-molecular medications are needed in the treatment of rheumatoid arthritis (RA). MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK)…
Abstract Number: 565 • 2014 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Jürgen Braun¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Owen Davies⁵, Tommi Nurminen⁴ and Desiree van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous results from RAPID-axSpA (NCT01087762) demonstrated that certolizumab pegol (CZP) reduced inflammation in the sacroiliac joints (SIJ) and spine, as assessed by Magnetic Resonance…
Abstract Number: 2495 • 2014 ACR/ARHP Annual Meeting
Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials
Chenglong Han¹, Edward C. Keystone², Roy Fleischmann³, Josef Smolen⁴, Eric L. Matteson⁵, Paul Emery⁶, Mark C Genovese⁷, Timothy A. Gathany¹ and Elizabeth C. Hsia^8,9, ¹Janssen Global Services, LLC., Malvern, PA, ²University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ³Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ⁴Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Janssen Research & Development, LLC., Spring House, PA, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: To assess the impact of golimumab (GLM) on physical function and employability in patients with rheumatoid arthritis (RA) with various prior treatment histories, after…
Abstract Number: 1490 • 2014 ACR/ARHP Annual Meeting
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
Anaïz Nutz¹, Yohan Duny², Thomas Barnetche³, Jacques Morel⁴, Bernard Combe⁵ and Claire Daien⁶, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²INSERM, Montpellier, France, ³Department of rheumatology, Bordeau, France, ⁴Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Hopital Lapeyronie, Montpellier, France
Background/Purpose Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint and bone destruction. Loss of bone in RA is not only localized in…
Abstract Number: 545 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Philip J. Mease¹, Roy Fleischmann², Jurgen Wollenhaupt³, Atul A. Deodhar⁴, Dafna D. Gladman⁵, Bengt Hoepken⁶, Luke Peterson⁷ and Désirée M. van der Heijde⁸, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Oregon Health and Sciences University, Portland, OR, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶UCB Pharma, Monheim, Germany, ⁷Biostatistics US Group, UCB Pharma, Raleigh-Durham, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 48 weeks (wks) in psoriatic arthritis (PsA) patients (pts), including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].